Allergan settles with one of four companies contesting Restasis patent

(Reuters) – Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply